Excerpt from Siren Biotechnology press release.

Siren Biotechnology is transforming how we treat cancer. By merging the precision of gene therapy with the power of immunotherapy, we’re creating a new kind of off-the-shelf treatment: one that teaches the body’s immune system to find and destroy cancer cells. 

Siren is the world’s first universal adeno-associated virus (AAV) immuno-gene therapy, designed to be effective across multiple cancers, making the next generation of cancer therapy accessible and scalable. 

Led by world-renowned scientists and biotech innovators, Siren’s team brings expertise from Stanford, UCSF, Duke, Mount Sinai, Roche, and multiple leading gene therapy companies. 

Our pioneering approach to cancer treatment is backed by $28 million in funding from marquee investors, with preclinical data showing curative results in animal studies, including eliminating tumors entirely in the majority of animals.

Founders Fund, Lux Capital, Innovation Endeavors – VC’s who have backed industry-defining companies like OpenAI, Spotify, Airbnb, and Zocdoc – all believe Siren is redefining the future of cancer treatment in a $3.2B+ market.

Cancer is the second leading cause of death worldwide, claiming over 10 million lives every year.

Gliomas, the most common malignant brain tumors, impact over 20,000 people each year in the U.S. alone. High-grade glioma, the most aggressive and prevalent form of glioma, has a median survival of just 12–18 months.

Traditional treatments, such as chemotherapy and radiation, are limited in their effectiveness, can harm healthy tissues, and fail to improve patient survival rates in some of the deadliest cancers.

The last FDA-approved treatment for adults with high-grade glioma was over 20 years ago. For patients facing the most dire cancers, innovation has largely stagnated, leaving them with few effective options. 

For traditional gene therapy, new solutions often take over a decade and billions of dollars to develop and are focused on a single disease.

At Siren, we’re pioneering a revolutionary approach to treating cancer using an established gene therapy tool called adeno-associated virus (AAV).

AAV is a safe virus that acts like a microscopic mail carrier — delivering medicine directly where it’s needed.

It’s exceptionally skilled at delivering precise instructions to specific areas of the body and has been used for decades to successfully treat genetic blindness, muscular disorders, and a pediatric form of Parkinson’s disease.

Now, we’re using it to train the body’s immune system to find and destroy cancer.

By sending cancer-fighting instructions straight into tumors, AAV helps the body recognize cancer cells as a threat and activates the immune system to eliminate them.

This makes it a powerful and precise tool for treating cancer safely and effectively.

Most cancer treatments rely on chemotherapy, radiation, or surgery - methods that often damage healthy cells and come with serious side effects like nausea, fatigue, and long-term organ damage.

Siren’s approach is different.

We’re starting with brain cancers, some of the most aggressive and devastating cancers, due to their low survival rates, high unmet need, and streamlined regulatory path.

Success here could change outcomes for those facing this devastating disease and pave the way for treating countless other cancers.

In preclinical studies with over 550 animals treated, our therapy has already demonstrated curative potential, eliminating tumors and achieving an 86%survival rate — a major step toward human trials.

Our treatment is designed to work across multiple cancer types. Because our therapy targets solid tumors without needing to match specific mutations or antigens, we don’t have to re-engineer new therapies for each new cancer.

That means we can move faster and help more people.

Siren solves a key problem with current treatments: traditional gene therapies are developed one-to-one for a single disease, and traditional cancer drugs are often ineffective in brain cancers.

Our approach reduces development timelines and capital needs per program, allowing us to treat patients faster. Siren has the potential to change the oncology landscape forever.

Siren's innovative platform is protected by four pending patent families that cover critical advancements in gene therapy delivery, safety, and scalability in cancer treatment, including:

• Our AAV immuno-gene therapy platform
• Breakthroughs in AAV genome design that reduce unwanted immune responses and make therapies safer and more effective
• Regulatory elements that improve the safety and strength of Siren’s gene therapies
• Manufacturing methods that ensure the quality and scalability as we grow

This strong IP moat gives us a significant competitive edge and a clear path to market.

Siren's team is a powerhouse of visionary scientists and biotech innovators from top institutions like Stanford, UCSF, Duke, Mount Sinai, and Roche.

Dr. Nicole Paulk, Siren’s Founder and CEO, is a global expert in AAV gene therapy, having developed next-generation viral platforms now used by dozens of biotech companies.

She has shaped FDA regulatory guidance and advised leading biopharma companies, including Sarepta, Astellas, and Dyno Therapeutics.

From breakthroughs in AAV manufacturing and vector engineering to scaling biotech innovations into real-world treatments, our team brings the expertise and industry leadership needed to turn cutting-edge science into life-changing cancer therapies.

We're guided by an advisory board of globally recognized leaders whose groundbreaking contributions have shaped the fields of gene therapy, oncology, and immunobiology.

Dr. Samuel Blackman has played a pivotal role in securing the first FDA approval for a pediatric brain cancer treatment in nearly 30 years. 

Dr. Mustafa Khasraw has led numerous clinical trials in neuro-oncology and cancer immunotherapy, redefining how some of the toughest cancers are treated and improving outcomes for thousands of patients.

On the gene therapy front, Dr. Beverly Davidson is a pioneer. As the co-founder of Spark Therapeutics, she helped bring Luxturna – the first FDA-approved AAV gene therapy – to life, leading to its acquisition by Roche in a $4.8B deal. 

Meanwhile, Dr. Leonidas Platanias, Director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, runs one of the nation’s top clinical trial centers and is a world expert in the very cytokines we use in our therapy.

The total addressable market for Siren’s groundbreaking therapy is driven by the urgent need for more effective brain cancer treatments.

The global brain tumor therapeutics market grew from $3.03 billion in 2023 to $3.28 billion in 2024 and is expected to continue its rapid expansion, reaching $5.28 billion by 2030 at a CAGR of 8.24%. 

In the U.S. alone, the brain cancer therapeutics market was valued at $966 million in 2022 and is projected to nearly double to $1.87 billion by 2030, growing at a CAGR of 8.6%.

This growth reflects the increasing demand for innovative therapies to combat aggressive and often fatal brain cancers.

Siren is uniquely positioned to lead this market, offering a powerful new approach that could redefine brain cancer treatment and establish a new standard of care.

Siren Biotechnology operates on a proven therapeutics biotech model, generating future revenue through FDA-approved therapy sales and pharmaceutical partnerships.

Once our universal AAV immuno-gene therapy is available to patients, we aim to generate revenue via treatment insurance reimbursements.

In addition to direct sales of our therapy, we will explore potential partnerships that may grant pharmaceutical companies the use of our therapies for specific cancer types. 

These partnerships could generate additional revenue through upfront payments, milestone-based payments, and royalties on future sales. Additionally, these co-development agreements could allow us to expand our reach while maintaining control over our universal platform.

We’re accelerating the development of potentially life-saving therapies by utilizing expedited FDA programs designed for high-need, rare diseases like deadly brain cancers.

This has the potential to cutyears off traditional timelines and allow us to bring transformative treatments to patients faster.

The gene therapy space has seen a series of successful exits, with several companies achieving multi-billion-dollar valuations or acquisitions.

Siren's unique positioning at the intersection of two high-growth markets — AAV gene therapy and cancer treatment – sets us up for even stronger outcomes.

We're building a company for a successful exit; FDA approval, licensing, and co-developments will help us scale quickly. Siren’s IP bridges the oncology and AAV gene therapy spaces, creating novel partnership opportunities and unique valuation potential.

We’re on a mission to transform the world’s deadliest cancers into treatable diseases and bring hope to millions. Our universal AAV gene therapy platform is pioneering a scalable, groundbreaking approach to cancer care.

By investing, you’re not just supporting innovation; you’re joining a movement to bring potentially life-saving therapies to patients facing some of the world's deadliest cancers. 

Let’s change the future of cancer care, together. Invest today.